Another biotech shuffles its C-suite as Silence CEO steps down

Silence Therapeutics became the latest biotech to see its chief executive hit the exit.

Mark Rothera is leaving effective immediately, Silence announced late Monday, marking the end of his roughly 17-month tenure. In his place, the biotech elevated CFO Craig Tooman to the CEO and president roles, where he’ll attempt to shepherd a slate of early-stage and preclinical RNAi programs forward.